FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2284660176> ?p ?o ?g. }

• W2284660176 endingPage "e0149697" @default.
• W2284660176 startingPage "e0149697" @default.
• W2284660176 abstract "Introduction There are few drugs with proven efficacy in cutaneous leishmaniasis (CL), and pentavalent antimonial derivatives are still the main first-line therapeutic agents worldwide, despite their recognized high toxicities. Randomized controlled clinical trials assessing the efficacy and safety of new therapeutic modalities are of high priority, and the definition of the design of such trials raises debate about the use of placebo as a comparator. To support the use of placebo as a comparator, two main points need to be addressed: 1- the cure rate without any therapeutic intervention and 2- the damage caused by CL and its impact on patients. Objective The aim of this study was to systematically assess the spontaneous cure rate for American CL and to broaden the discussion about placebo use in CL trials. Methods The PRISMA guidelines for systematic reviews and the Cochrane manual were followed. The sources used were the PubMed and LILACS databases. Studies were included if they reported cure rates using placebo or no treatment in American CL. Results Thirteen studies of a total of 352 patients were ultimately included in this review. The summarized global cure rates for all Leishmania species according to the intention-to-treat analyses performed at approximately three (“initial cure”) and nine (“definitive cure”) months after “no treatment” or placebo use were 26% (CI95%: 16 to 40%) and 26% (CI95%:16 to 38%), respectively. Notably, a significantly lower cure rate was observed for L. braziliensis infection (6.4%, CI95%:0.2 to 20%) than for L. mexicana infection (44%, CI95%:19 to 72%), p = 0.002. Of note, relapse occurred in 20% of patients with initial healing (CI95%:9.2 to 38.9%). Conclusion These results clearly demonstrate a low spontaneous cure rate following no-treatment or placebo use, confirming that this strategy for the control group in CL studies expose patients to greater morbidity, especially for CL caused by L. braziliensis. Therefore, from this point, the crucial questionto consider regarding placebo use isthe seriousness of the suffering caused by this disease." @default.
• W2284660176 created "2016-06-24" @default.
• W2284660176 creator A5002493348 @default.
• W2284660176 creator A5008848921 @default.
• W2284660176 creator A5023914324 @default.
• W2284660176 creator A5048905313 @default.
• W2284660176 creator A5056476559 @default.
• W2284660176 creator A5068233973 @default.
• W2284660176 date "2016-02-19" @default.
• W2284660176 modified "2023-09-26" @default.
• W2284660176 title "The Cure Rate after Placebo or No Therapy in American Cutaneous Leishmaniasis: A Systematic Review and Meta-Analysis" @default.
• W2284660176 cites W1517487519 @default.
• W2284660176 cites W1963947842 @default.
• W2284660176 cites W1979190970 @default.
• W2284660176 cites W1984069235 @default.
• W2284660176 cites W1987467897 @default.
• W2284660176 cites W1995191885 @default.
• W2284660176 cites W2005875868 @default.
• W2284660176 cites W2009469065 @default.
• W2284660176 cites W2011083855 @default.
• W2284660176 cites W2027175212 @default.
• W2284660176 cites W2038428220 @default.
• W2284660176 cites W2048941556 @default.
• W2284660176 cites W2049434392 @default.
• W2284660176 cites W2057228350 @default.
• W2284660176 cites W2057424462 @default.
• W2284660176 cites W2069498867 @default.
• W2284660176 cites W2088831588 @default.
• W2284660176 cites W2097202300 @default.
• W2284660176 cites W2111597581 @default.
• W2284660176 cites W2118555120 @default.
• W2284660176 cites W2120726511 @default.
• W2284660176 cites W2123328954 @default.
• W2284660176 cites W2130139393 @default.
• W2284660176 cites W2133965525 @default.
• W2284660176 cites W2171501803 @default.
• W2284660176 cites W2217750255 @default.
• W2284660176 cites W2285587194 @default.
• W2284660176 cites W2312621854 @default.
• W2284660176 cites W2330770341 @default.
• W2284660176 cites W2472577208 @default.
• W2284660176 cites W3022903699 @default.
• W2284660176 cites W4252564070 @default.
• W2284660176 cites W4253833997 @default.
• W2284660176 cites W4292528167 @default.
• W2284660176 doi "https://doi.org/10.1371/journal.pone.0149697" @default.
• W2284660176 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4760744" @default.
• W2284660176 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26894430" @default.
• W2284660176 hasPublicationYear "2016" @default.
• W2284660176 type Work @default.
• W2284660176 sameAs 2284660176 @default.
• W2284660176 citedByCount "35" @default.
• W2284660176 countsByYear W22846601762016 @default.
• W2284660176 countsByYear W22846601762017 @default.
• W2284660176 countsByYear W22846601762018 @default.
• W2284660176 countsByYear W22846601762019 @default.
• W2284660176 countsByYear W22846601762020 @default.
• W2284660176 countsByYear W22846601762021 @default.
• W2284660176 countsByYear W22846601762022 @default.
• W2284660176 countsByYear W22846601762023 @default.
• W2284660176 crossrefType "journal-article" @default.
• W2284660176 hasAuthorship W2284660176A5002493348 @default.
• W2284660176 hasAuthorship W2284660176A5008848921 @default.
• W2284660176 hasAuthorship W2284660176A5023914324 @default.
• W2284660176 hasAuthorship W2284660176A5048905313 @default.
• W2284660176 hasAuthorship W2284660176A5056476559 @default.
• W2284660176 hasAuthorship W2284660176A5068233973 @default.
• W2284660176 hasBestOaLocation W22846601761 @default.
• W2284660176 hasConcept C126322002 @default.
• W2284660176 hasConcept C141071460 @default.
• W2284660176 hasConcept C142724271 @default.
• W2284660176 hasConcept C168563851 @default.
• W2284660176 hasConcept C17744445 @default.
• W2284660176 hasConcept C177713679 @default.
• W2284660176 hasConcept C189708586 @default.
• W2284660176 hasConcept C199539241 @default.
• W2284660176 hasConcept C203014093 @default.
• W2284660176 hasConcept C204787440 @default.
• W2284660176 hasConcept C27081682 @default.
• W2284660176 hasConcept C2776555147 @default.
• W2284660176 hasConcept C2778702967 @default.
• W2284660176 hasConcept C2779473830 @default.
• W2284660176 hasConcept C2994123057 @default.
• W2284660176 hasConcept C535046627 @default.
• W2284660176 hasConcept C71924100 @default.
• W2284660176 hasConceptScore W2284660176C126322002 @default.
• W2284660176 hasConceptScore W2284660176C141071460 @default.
• W2284660176 hasConceptScore W2284660176C142724271 @default.
• W2284660176 hasConceptScore W2284660176C168563851 @default.
• W2284660176 hasConceptScore W2284660176C17744445 @default.
• W2284660176 hasConceptScore W2284660176C177713679 @default.
• W2284660176 hasConceptScore W2284660176C189708586 @default.
• W2284660176 hasConceptScore W2284660176C199539241 @default.
• W2284660176 hasConceptScore W2284660176C203014093 @default.
• W2284660176 hasConceptScore W2284660176C204787440 @default.
• W2284660176 hasConceptScore W2284660176C27081682 @default.
• W2284660176 hasConceptScore W2284660176C2776555147 @default.
• W2284660176 hasConceptScore W2284660176C2778702967 @default.

• next